Teva Pharmaceutical (TEVA)

He loves the space. Nobody wants these companies. There is tremendous value. He has a model price of $52, and this closed at $29.01, an 80% upside. He would buy the name, but if there was a negative transit again of EBV -1 of $27.32, he would exit the position. Sees a lot of value. (See Top Picks.)

This has had a really tough few quarters. There have been a few stumbling blocks on the FDA front and on competition, but she would say that it is bottoming out at this time. Valuation wise, it is very, very attractive. 4.9% dividend yield.

This has had a really difficult time in the last 12 months. There is a lot of worry about drug pricing. He would step aside for now, but keep an eye on it. There will be a return of interest in this name.

A generic manufacturer of drugs. It’s been a good business for many, many years. There had been a bit of a downturn, and they had to sell some assets to stay at the same level they were at. According to his numbers, that was a good move, as returns are starting to move back up.

The largest generic manufacturer of drugs. They got themselves in trouble in the last number of years by trying to become an actual Pharma company with R&D, with not great success. The generic business is very price intensive. It is not an R&D company, it is a manufacturer. He would pass on this.

The world’s largest drug manufacturer. They are reporting tomorrow morning. The generic drug prices in the US have remained under significant pressure. He sold his holdings in January. There is a very low price to earnings, but their business is in decline. 4.3% dividend yield.

It was announced this was going to be investigated in terms of unfair practices. That was post the loss of the Copaxon drug, which was their branded pharmaceutical. This was followed by a small announcement that Israel was effectively going to do the same thing. He would be more afraid of the US than the Israeli regulators. At this level, it is at fairly attractive level for them to turn it around. The balance sheet is reasonable. A higher risk, so he wouldn’t have them in his portfolios.

Made a large acquisition and there are always execution risks on any acquisition. They’re also going through a CEO search, and need to bring someone in who has a global pharmaceutical picture, and can drive the company forward. Every pharmaceutical company had been hurt leading up to the election, and that was not followed by the bounce that had been expected. The one positive thing about this company is that generics will continue to do well. Their recent acquisition was a good one and they can take out a lot of costs. Besides generics, there are labelled drugs they are working on, which will help in the next several years. Not an expensive stock and pays a great dividend. However, there is a lot of “wait and see” on these things. Feels that if you buy it here and hold it, you will do well over the next several years.

A cheap, but troubled stock. It is the leading generics pharmaceutical provider globally. They overextended themselves a while ago, in trying to get into specialty Pharma areas, which has been a bit of a problem. Expected to generate a little over $5 in earnings next year, a 6X earnings multiple. The Pharma sector as a whole tends to be 3X, so this is very, very cheap. The dividend is over 4%. The negative is that the management team is in flux. Also, the Department of Justice now has an inquiry into price fixing potential by the generic providers. The balance sheet is incredibly levered at 4.8X EBITDA. This is worth taking a half position and then growing that out. If things start to normalize and they get the earnings they are projecting, it should really start seeing 20%, 30%, 40% growth from here.

Made a huge acquisition and overpaid massively for it. The generic drug industry is a competitive industry. The patent is there for anybody to look at. It looks cheap, but they still have a big slug of debt from their acquisition.

The largest generic company globally. They need a new CEO. They acquired Allergan. There are a lot of things happening, so it is a wait and see story. A very good company and incredibly cheap. They can maintain their dividend yield, which he thinks is at about 4%.

He looks at technical and fundamental. Technically you don’t have backup from the fundamentals. You need to see the chart validated.

The 200 day, 50 day and 100 day moving averages have all fallen. The price is below those averages, so there hasn’t been a breakthrough. However, there seems to be a bit of a basing pattern over the last few months. Is it going to start the shares rebounding? It’s hard to say. It could be a bit of a value trap at this point.

It was a pick two shows ago. Soon after buying it he sold at a loss. He bought it because it was selling at historically low valuations. Very shortly after, the CEO abruptly quit and no reason has been given.

(A Top Pick Jan 17/17. Down 1%.) He is not investing for only 2 months, but for at least 12 months. Healthcare is still under pressure. This is #1 in generics globally.